Literature DB >> 14516531

PET Studies of the Effect of the Antidepressant Drugs Nefazodone or Paroxetine on [11C]Raclopride Binding in Human Brain.

Joanna S. Fowler1, Gene Jack Wang, Nora D. Volkow, John Ieni, Jean Logan, Naomi Pappas, Stephen L. Dewey.   

Abstract

Serotonin modulates dopamine release in the striatum. In this study we set out to determine whether nefazodone and paroxetine, two antidepressant drugs that interact with the brain serotonin system, produce detectable changes in synaptic dopamine in vivo in the human brain using positron emission tomography (PET) and [11C]raclopride, a dopamine D-2 receptor specific radiotracer that is sensitive to changes in synaptic dopamine. Three normal healthy human volunteers had 4 PET/[11C]raclopride scans each in 2 sessions. In the first session, subjects had a baseline [11C]raclopride scan and a second scan 1 hour following the oral administration of either nefazodone (200 mg PO) or paroxetine (20 mg PO). Four to 6 weeks later, in a second PET/[11C]raclopride session, the same subjects received the other drug for comparison. Neither nefazodone nor paroxetine produced significant changes in [11C]raclopride binding. This and other reports in the literature indicate that different drugs that affect the serotonin system do not produce consistent and predictable changes in [11C]raclopride binding and that a full understanding of their actions on serotonin and the associated changes in dopamine requires further investigation.

Entities:  

Year:  1999        PMID: 14516531     DOI: 10.1016/s1095-0397(99)00028-x

Source DB:  PubMed          Journal:  Clin Positron Imaging        ISSN: 1095-0397


  2 in total

1.  Biodistribution and radiation dosimetry of [11C]raclopride in healthy volunteers.

Authors:  Maria-João Ribeiro; Marcel Ricard; Sandrine Bourgeois; Marie-Angele Lièvre; Michel Bottlaender; Philippe Gervais; Frédéric Dollé; André Syrota
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04-20       Impact factor: 9.236

2.  Selective serotonin reuptake inhibitor (SSRI) modulation of striatal dopamine measured with [11C]-raclopride and positron emission tomography.

Authors:  Gwenn S Smith; Yilong Ma; Vijay Dhawan; Thomas Chaly; David Eidelberg
Journal:  Synapse       Date:  2009-01       Impact factor: 2.562

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.